Pharmacytimes: Condition Center: Cardiovascular Health Cardiovascular Health en-us Sun, 26 Mar 2017 08:56:32 UTC Sun, 26 Mar 2017 08:56:32 UTC Could Pharmacogenetic Dosing Reduce Warfarin-Related Adverse Events? Personalizing doses of warfarin through genetic testing helped reduce the risk of combined adverse events in patients undergoing elective orthopedic surgery, according to data presented at the American College of Cardiology's 66th Annual Scientific Session.  1:19 PM, Mon March 20, 2017 Younger Women Less Likely to Receive Preventive Care for Heart Disease Younger women are less likely to be screened for cardiovascular disease (CVD) and treated with preventive medicine than men, a recent study found.  2:52 PM, Mon March 6, 2017 Drug Shortages: Manufacturer Accountability Increasing All over the world, drug shortages cause complex and risky adjustments to medical regimens.  8:00 AM, Thu February 23, 2017 Sodium-Glucose Cotransporter 2 Inhibitors: Possible Role in Cardiology Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging antidiabetic class that offer significant cardiovascular risk reduction. 10:14 AM, Tue January 10, 2017 Aspirin, Omeprazole Combination Treatment Yosprala Approved The FDA recently approved Aralez Pharmaceuticals’ Yosprala, a once-daily, fixed-dose combination of the antiplatelet agent aspirin and the proton pump inhibitor omeprazole. 7:00 AM, Mon September 26, 2016 3 Common Barriers to Cardiac Medication Adherence Pharmacists can help evaluate and address adherence barriers among patients taking medications for cardiovascular disease. 8:54 AM, Wed May 18, 2016 Cardiovascular Medication Adherence Not Commonly Discussed with Physicians Despite advances in preventative drug therapy, cardiovascular disease remains the leading cause of death in the United States. 4:45 AM, Wed May 18, 2016 Entresto Shows Benefit Even in Clinically Stable Heart Failure Patients Novartis’ sacubitril/valsartan (Entresto) is showing promise for heart failure patients with reduced ejection fraction, regardless of background therapy or clinical stability. 7:00 AM, Thu April 14, 2016 Early Follow-Up Care After Heart Attack Key to Medication Adherence Patients receiving follow-up care more than 6 weeks after a heart attack are much less likely to stick to their medication regimen. 10:30 PM, Wed March 23, 2016 FDA Rejects New Indication for Zetia and Vytorin Merck has received a complete response letter from the FDA regarding its supplemental new drug applications for ezetimibe and ezetimibe and simvastatin. 7:00 AM, Thu February 18, 2016 ACS Patient Nonadherence Factors Pharmacists Should Target Seven in 10 patients report some extent of nonadherence prior to a hospitalization caused by a cardiovascular event such as acute cardiac failure. 12:00 AM, Fri November 6, 2015 Parkinson's Drug Does Not Increase Risk of Cardiovascular Events The FDA has determined that entacapone, a drug used in the treatment of Parkinson's disease, does not increase patients' risk of heart attacks, stroke, or other cardiovascular events. 9:03 PM, Tue October 27, 2015 What Hinders Good Heart Health Among African-Americans? Cardiovascular disease (CVD) is the most common cause of death in America, but the disease rates for African-Americans are especially high. 10:00 PM, Sun October 11, 2015 Does DAPT Work as Well for Stroke as It Does for ACS? Dual antiplatelet therapy (DAPT) with aspirin and another antiplatelet agent such as clopidogrel, prasugrel, or ticagrelor is the go-to preventive therapy for patients who have experienced certain cardiovascular events. 8:00 AM, Sat October 3, 2015 Time to SPRINT to Lower Blood Pressure Target? A target systolic blood pressure (SBP) of 120 mm Hg has outperformed the recommended 140 mm Hg target in the landmark SPRINT study. 12:18 AM, Mon September 14, 2015 Gout Means Greater Risk for Atrial Fibrillation Gout patients may be at greater risk for atrial fibrillation. 9:00 PM, Tue September 8, 2015 Colchicine in Cardiovascular Disease: Old Drug, New Use Colchicine (Colcrys) is a promising adjunctive option in secondary prevention of cardiovascular events, probably because of its ability to stop or slow neutrophil reaction to intravascular cholesterol crystals. 9:48 PM, Mon September 7, 2015 First-in-Class Heart Failure Drug Receives FDA Approval The FDA today approved sacubitril/valsartan for treating heart failure. 5:21 AM, Tue July 7, 2015 FDA Approves New Antiplatelet Treatment The FDA today approved The Medicines Company's cangrelor (Kengreal), an intravenous antiplatelet medication that can prevent blood clots from forming in the coronary arteries. 5:04 AM, Mon June 22, 2015 Diabetes Drug Won't Worsen Heart Failure Risk A study evaluating the cardiovascular safety of Merck's type 2 diabetes drug sitagliptin determined the dipeptidyl peptidase-4 inhibitor does not increase the risk for heart failure hospitalization. 10:00 PM, Sat June 13, 2015